

Accepted Manuscript

Formulation of levodopa containing dry powder for nasal delivery applying the quality-by-design approach

Csilla Bartos, Edina Pallagi, Piroska Szabó-Révész, Rita Ambrus, Gábor Katona, Tamás Kiss, Mernaz Rahimi, Ildikó Csóka



PII: S0928-0987(18)30365-8

DOI: doi:[10.1016/j.ejps.2018.07.061](https://doi.org/10.1016/j.ejps.2018.07.061)

Reference: PHASCI 4637

To appear in: *European Journal of Pharmaceutical Sciences*

Received date: 19 March 2018

Revised date: 1 July 2018

Accepted date: 31 July 2018

Please cite this article as: Csilla Bartos, Edina Pallagi, Piroska Szabó-Révész, Rita Ambrus, Gábor Katona, Tamás Kiss, Mernaz Rahimi, Ildikó Csóka , Formulation of levodopa containing dry powder for nasal delivery applying the quality-by-design approach. Phasci (2018), doi:[10.1016/j.ejps.2018.07.061](https://doi.org/10.1016/j.ejps.2018.07.061)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Formulation of levodopa containing dry powder for nasal delivery applying the quality-by-design approach

Csilla Bartos, Edina Pallagi, Piroska Szabó-Révész, Rita Ambrus, Gábor Katona, Tamás Kiss, Mernaz Rahimi, Ildikó Csóka*

Institute of Pharmaceutical Technology and Regulatory Affairs, University of Szeged, Szeged, Hungary

*Corresponding author: Ildikó Csóka

Institute of Pharmaceutical Technology and Regulatory Affairs, University of Szeged

H-6720 Szeged, Eötvös u. 6, Hungary

Tel: +36 62 545572

Fax: +36 62 545571

E-mail address: csoka@pharm.u-szeged.hu

ABSTRACT

The aim of this work was to carry out preliminary experiments for preparation of levodopa (LEVO)-containing intranasal powder. The experiments were designed according to the Quality by Design (QbD) concept. Based on prior risk assessment, LEVO and chitosan (CH) or sodium hyaluronate (HA) as mucoadhesive matrix formers were co-milled using planetary ball mill to prepare microparticles as drug delivery systems. The rotation speed, the milling time and the drug-additive ratio were evaluated to be the most relevant milling factors - as a result of the initial risk assessment; which were set according to a factorial design. The effects of critical process parameters and excipients were investigated on the particle size and surface characteristics of products, and on the crystallinity, *in vitro* dissolution and permeability of LEVO. Milling in the presence of higher amount of HA resulted in smaller average particle size of powders ($D_{50} = 13.068 \mu\text{m}$) and higher initial dissolution and permeation of LEVO compared to CH-containing formulations ($D_{50} = 21.667 \mu\text{m}$).

Download English Version:

<https://daneshyari.com/en/article/8510826>

Download Persian Version:

<https://daneshyari.com/article/8510826>

[Daneshyari.com](https://daneshyari.com)